Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc (NASDAQ: BYSI) is a clinical-stage biopharmaceutical leader advancing innovative cancer therapies through its Plinabulin pipeline and target protein degradation research. This page serves as the definitive source for verified company updates, providing investors and researchers with essential insights into therapeutic developments and strategic initiatives.
Access timely announcements spanning clinical trial progress, regulatory milestones, and partnership agreements. Our curated collection includes press releases on Plinabulin's multifaceted mechanism of action, updates from global Phase 3 studies, and innovations from the SEED Therapeutics collaboration. Each update is vetted for accuracy to support informed decision-making.
Bookmark this resource for structured access to BeyondSpring's scientific advancements in immuno-oncology and protein degradation technology. Regular updates ensure you maintain current awareness of the company's progress in addressing unmet needs in NSCLC and other oncology indications.
BeyondSpring Inc. (Nasdaq: BYSI), a clinical-stage biopharmaceutical company, announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2022, with the SEC on April 18, 2023. This report includes audited consolidated financial statements accessible via the SEC and BeyondSpring's website. The company emphasizes its commitment to providing free hard copies of its report to shareholders upon request.
BeyondSpring focuses on developing innovative therapies for patients with high unmet medical needs, leveraging its unique drug discovery platform. Its lead asset, Plinabulin, is under study for various cancer indications, with promising Phase 3 results in combination with chemotherapy to prevent neutropenia and improve survival rates in non-small cell lung cancer. The company also has multiple preclinical immuno-oncology assets.
BeyondSpring Inc. (NASDAQ: BYSI) reported significant milestones achieved by its subsidiary, SEED Therapeutics, in collaboration with Eli Lilly, resulting in $7 million in milestone payments. The company has completed enrollment in three investigator-initiated trials (IIT) for Plinabulin targeting various cancers. Research and development expenses have decreased to $25.6 million in 2022 from $36.9 million in 2021, while general and administrative expenses fell to $13.0 million from $30.7 million. Despite a net loss of $33.3 million for 2022, reduced expenses indicate improved operational efficiency. Upcoming milestones include NDA submissions for Plinabulin in China by mid-2023 for CIN and NSCLC indications.
BeyondSpring (NASDAQ: BYSI) announced the enrollment of the first patient in its Phase 2 trial for Plinabulin, combined with Merck's Keytruda and Docetaxel, targeting metastatic non-small cell lung cancer (NSCLC) patients who have experienced disease progression after immunotherapy. This study aims to address the significant unmet medical need among these patients, as anti-PD-1 therapies often lead to resistance. The trial is underway at Peking Union Medical College Hospital, with promising data suggesting that Plinabulin may enhance efficacy against advanced cancer, evidenced by a previously noted 40% response rate in a related study.
FAQ
What is the current stock price of Beyondspring (BYSI)?
What is the market cap of Beyondspring (BYSI)?
